Cervical Cancer
Oncology 2 original drugsOncology indication. Cervical Cancer has 2 FDA-approved novel treatments, led by SEAGEN, with 270 active industry clinical trials across 3 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Cervical Cancer Market Leaders
Companies with the most FDA-approved novel Cervical Cancer drugs.
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Cervical Cancer Treatments by Mechanism
Top 6 mechanisms across 8 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Cervical Cancer Clinical Pipeline by Phase
205 industry-sponsored trials across 137 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Cervical Cancer
Novel Cervical Cancer Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Cervical Cancer.
Reformulations (1 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Cervical Cancer Drug Targets
Molecular targets of approved and investigational Cervical Cancer drugs — 3 targets tracked.
Biosimilars (6 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Generic Drugs (2 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs